Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Center for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
J Card Fail. 2023 May;29(5):760-770. doi: 10.1016/j.cardfail.2022.10.423. Epub 2022 Nov 2.
The 6-minute walk test (6MWT) is widely used to measure exercise capacity; however, the magnitude of change that is clinically meaningful for individuals is not well established in heart failure with reduced ejection fraction (HFrEF).
To calculate the minimal clinically important difference (MCID) for change in exercise capacity in the 6MWT in iron-deficient populations with HFrEF.
In this pooled secondary analysis of the FAIR-HF and CONFIRM-HF trials, mean changes in the 6MWT from baseline to weeks 12 and 24 were calculated and calibrated against the Patient Global Assessment (PGA) tool (clinical anchor) to derive MCIDs in improvement and deterioration.
Of 760 patients included in the 2 trials, 6MWT and PGA data were available for 680 (89%) and 656 (86%) patients at weeks 12 and 24, respectively. The mean 6MWT distance at baseline was 281 ± 103 meters. There was a modest correlation between changes in 6MWT and PGA from baseline to week 12 (r = 0.31; P < 0.0001) and week 24 (r = 0.43; P < 0.0001). Respective estimates (95% confidence intervals) of MCID in 6MWT at weeks 12 and 24 were 14 meters (5;23) and 15 meters (3;27) for a "little improvement" (vs no change), 20 meters (10;30) and 24 meters (12;36) for moderate improvement vs a "little improvement,", -11 meters (-32;9.2) and -31 meters (-53;-8) for a "little deterioration" (vs no change), and -84 meters (-144;-24) and -69 meters (-118;-20) for "moderate deterioration" vs a "little deterioration".
The MCID for improvement in exercise capacity in the 6MWT was 14 meters-15 meters in patients with HFrEF and iron deficiency. These MCIDs can aid clinical interpretation of study data.
6 分钟步行试验(6MWT)被广泛用于测量运动能力;然而,对于射血分数降低的心力衰竭(HFrEF)患者,个体的临床意义上的变化幅度尚未得到很好的确定。
计算缺铁性 HFrEF 人群中 6MWT 运动能力变化的最小临床重要差异(MCID)。
在 FAIR-HF 和 CONFIRM-HF 试验的这一汇总二次分析中,从基线到第 12 周和第 24 周计算了 6MWT 的平均变化,并与患者整体评估(PGA)工具(临床锚)进行校准,以得出改善和恶化的 MCID。
在这两项试验的 760 名患者中,有 680 名(89%)和 656 名(86%)患者在第 12 周和第 24 周分别有 6MWT 和 PGA 数据。基线时 6MWT 的平均距离为 281±103 米。从基线到第 12 周(r=0.31;P<0.0001)和第 24 周(r=0.43;P<0.0001),6MWT 和 PGA 的变化之间存在适度相关性。第 12 周和第 24 周 6MWT 的 MCID 估计值(95%置信区间)分别为 14 米(5;23)和 15 米(3;27),用于“略有改善”(与无变化相比),20 米(10;30)和 24 米(12;36),用于“中度改善”与“略有改善”相比,-11 米(-32;9.2)和-31 米(-53;-8),用于“略有恶化”(与无变化相比),-84 米(-144;-24)和-69 米(-118;-20),用于“中度恶化”与“略有恶化”相比。
在缺铁性 HFrEF 患者中,6MWT 运动能力改善的 MCID 为 14 米-15 米。这些 MCID 可以帮助临床解释研究数据。